CD8A and myeloid sarcoma: To examine the general potential of CD4+ and CD8+ T-cells from natalizumab-treated and untreated MS patients to express effector cytokines, we measured the cytokine production in response to PMA/ionomycin in cell cultures that had not been exposed to antigen.